Skip to main content Skip to main navigation menu Skip to site footer

Association of neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women

  • Vania Idelia Winantyo ,
  • Vidi Vianney Chrisana Magrit Tanggo ,
  • Iskandar Ali ,

Abstract

Background: Breast cancer in young women is one of the leading causes of cancer death in young women worldwide, including in Indonesia. Most patients come to the hospital at the advanced stage. Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced breast cancer. However, half of breast cancer patients had a negative response to therapy.  

Methods: A retrospective cohort, analytic observational study to determine the association between NLR and anthracycline-based NAC clinical response in locally advanced young age breast cancer in Dr. Soetomo General Hospital, Surabaya.

Results: We analyze a total of 44 patients. 81.8% had stage IIIB, 93.2% >50 mm tumor size. Most of the cases had invasive ductal carcinoma type (86.4%), grade 3 (52.3%), and Luminal B HER2-negative type (34.1%). 52.3% of patients had a negative clinical response. The mean NLR was 3.07 ± 1.69, with a cut-off value of 2.805. There was no significant association between age, tumor size, histopathological type, grade, and subtype with neoadjuvant chemotherapy clinical response. There was a significant relationship between NLR with anthracycline-based NAC clinical response in locally advanced young age breast cancer (p < 0.001).

Conclusion: There was a significant relationship between NLR with the anthracycline-based neoadjuvant chemotherapy clinical response in young women with LABC.

References

  1. Siegel, RL, Miller, KD, Fuchs, HE, Jemal, A. Cancer statistics. CA Cancer J Clin. 2022. https://doi.org/10.3322/caac.21708.
  2. Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427. Published 2014 Aug 27. doi:10.1186/s13058-014-0427-5.
  3. Anwar SL, Raharjo CA, Herviastuti R, et al. Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based study. BMC Womens Health. 2019;19(1):28. Published 2019 Feb 6. doi:10.1186/s12905-019-0724-3.
  4. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649. doi:10.1016/j.annonc.2020.09.010.
  5. Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(4):452-478. doi:10.6004/jnccn.2020.0016.
  6. Sudarsa, I., Manuaba, I., Maliawan, S., Sutirtayasa, I. High Ki-67 and Vascular Endothelial Growth Factor (VEGF) Protein expression as negative predictive factor for combined neoadjuvant chemotherapy in young age stage III breast cancer. Bali Medical Journal. 2016;5(2). p226-236. DOI:10.15562/bmj.v5i2.207.
  7. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606-616. doi:10.1634/theoncologist.9-6-606.
  8. Chen J, Deng Q, Pan Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio. 2015;5:502-507. Published 2015 May 12. doi:10.1016/j.fob.2015.05.003.
  9. Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33-38. doi:10.1016/j.breast.2018.12.014.
  10. Asano Y, Kashiwagi S, Onoda N, et al. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. Ann Surg Oncol. 2016;23(4):1104-1110. doi:10.1245/s10434-015-4934-0.
  11. Wu L, Saxena S, Awaji M, Singh RK. Tumor-Associated Neutrophils in Cancer: Going Pro. Cancers (Basel). 2019;11(4):564. Published 2019 Apr 19. doi:10.3390/cancers11040564.
  12. Uribe-Querol E, Rosales C. Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res. 2015;2015:983698. doi:10.1155/2015/983698.
  13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026.
  14. Devi DG, Ishardyanto H. Young Age Breast Cancer: Profiles and Overall Survival in Dr. Soetomo Oncology Center, Surabaya, Indonesia. EJSO. 2020;46(2):63–4.
  15. Fu J, Wu L, Fu W, et al. How Young Is Too Young in Breast Cancer?-Young Breast Cancer Is Not a Unique Biological Subtype. Clin Breast Cancer. 2018;18(1):e25-e39. doi:10.1016/j.clbc.2017.05.015.
  16. Agarwal R, Unnikrishnan UG, Keechilat P, Rajanbabu A, Jose W, Vijaykumar DK. Pathological Complete Response in Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy: Survival Outcome and Its Relevance as a Surrogate End Point. South Asian J Cancer. 2020;9(3):136-140. doi:10.1055/s-0040-1721238.
  17. Purnawaty A, Hamdani W, Djaya I. Relationship of Grade, Intrinsic Subtype, and Clinical Response to Neoadjuvant Chemotherapy in Breast Cancer. IJSBAR. 2018;37(1):34–42.
  18. Ryspayeva D, Lyashenko A, Dosenko I, Kostryba O, Koshyk O, Krotevych M, et al. Predictive factors of pathological response to neoadjuvant chemotherapy in patients with breast cancer. JBUON. 2020;25(1):168–75.
  19. Rehman B, Parvaiz MA. Predictive factors involved in determining response to neoadjuvant chemotherapy in breast cancer and impact of response on 5 years disease free survival and overall survival. Eur J Cancer. 2020;138(Supplement 1):S40. DOI: 10.31487/j.COR.2020.08.05.
  20. Stamatovic L, Susnjar S, Gavrilovic D, Minic I, Ursulovic T, Dzodic R. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients. J BUON. 2018;23(5):1273-1280.
  21. Yarso K, Sudarsa IW, Wibawa-Manuaba I. Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study). Bali Med J. 2012;1(1):12–6.
  22. Zeidman M, Alberty-Oller JJ, Ru M, et al. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study. Breast Cancer Res Treat. 2020;184(1):203-212. doi:10.1007/s10549-020-05809-w.
  23. Mealey NE, O'Sullivan DE, Pader J, et al. Mutational landscape differences between young-onset and older-onset breast cancer patients. BMC Cancer. 2020;20(1):212. Published 2020 Mar 12. doi:10.1186/s12885-020-6684-z.
  24. Chen MB, Zhu YQ, Xu JY, et al. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS One. 2012;7(6):e39655. doi:10.1371/journal.pone.0039655.
  25. Tominaga N, Naoi Y, Shimazu K, et al. Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. Ann Oncol. 2012;23(12):3051-3057. doi:10.1093/annonc/mds120.
  26. Sella T, Gelber SI, Poorvu PD, et al. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2021;186(1):157-165. doi:10.1007/s10549-020-05989-5.
  27. Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020;18(1):33. Published 2020 Feb 28. doi:10.1186/s12964-020-0527-z.
  28. Liu C, Xing H, Guo C, Yang Z, Wang Y, Wang Y. MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways. Cell Cycle. 2019;18(18):2215-2227. doi:10.1080/15384101.2019.1638182.
  29. Qu Y, Dou B, Tan H, Feng Y, Wang N, Wang D. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol Cancer. 2019;18(1):69. Published 2019 Mar 30. doi:10.1186/s12943-019-0992-4.
  30. Wihandani D, Adiputra P, Supadmanaba I. Low prevalence of Caveolin-1 oncogenic polymorphism G14713A and T29107A among breast cancer patient in Sanglah General Hospital. Bali Medical Journal. 2017;6(3): S109-S112. DOI:10.15562/bmj.v6i3.743.
  31. Mendoza-Rodríguez M, Arévalo Romero H, Fuentes-Pananá EM, Ayala-Sumuano JT, Meza I. IL-1β induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells. Cancer Lett. 2017;390:39-44. doi:10.1016/j.canlet.2017.01.005.
  32. Stanton SE, Disis MLClinical significance of tumor-infiltrating lymphocytes in breast cancer. Journal for ImmunoTherapy of Cancer 2016;4:59. doi: 10.1186/s40425-016-0165-6.
  33. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405-414. doi:10.1038/nri3845.

How to Cite

Vania Idelia Winantyo, Vidi Vianney Chrisana Magrit Tanggo, & Iskandar Ali. (2022). Association of neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women. Bali Medical Journal, 11(2), 602–608. https://doi.org/10.15562/bmj.v11i2.3564

HTML
0

Total
0

Share

Search Panel

Vania Idelia Winantyo
Google Scholar
Pubmed
BMJ Journal


Vidi Vianney Chrisana Magrit Tanggo
Google Scholar
Pubmed
BMJ Journal


Iskandar Ali
Google Scholar
Pubmed
BMJ Journal